APOBEC3 & Breast Cancer: Therapy Resistance Link
- A new study published in Nature Genetics suggests that APOBEC3 mutagenesis frequently mediates therapy resistance in breast cancer (BC).
- Breast cancer remains the most common cancer among women, with the American Cancer Society estimating over 300,000 new cases of invasive BC will be diagnosed this year.
- This stems from the disease's heterogeneity and mutations affecting genes like ESR1, NF1, and HER2, which can lead to resistance against antiestrogens, CDK4/6 inhibitors, and PI3K inhibitors.
New research unveils a critical link: APOBEC3 mutagenesis may drive therapy resistance in breast cancer.The study, published in Nature Genetics, indicates that these enzymes could serve as a predictive biomarker for identifying tumors prone to resistance, potentially revolutionizing treatment strategies. analyzing nearly 4,000 breast cancer samples,the researchers found that APOBEC3 enzymes,while typically involved in fighting viruses,can trigger DNA changes and higher levels correlated with poor outcomes.These patterns are particularly prevalent in metastatic breast cancer. News Directory 3 explores the potential of APOBEC3-based biomarkers to guide the use of existing therapies and accelerate targeted treatment strategies. This growth represents a critical step toward overcoming resistance and personalizing treatment. Discover what’s next in the fight against breast cancer.
APOBEC3 Mutagenesis Linked to Breast Cancer Therapy Resistance
A new study published in Nature Genetics suggests that APOBEC3 mutagenesis frequently mediates therapy resistance in breast cancer (BC). The research highlights the potential of APOBEC3 as both a biomarker and a target for overcoming this resistance.
Breast cancer remains the most common cancer among women, with the American Cancer Society estimating over 300,000 new cases of invasive BC will be diagnosed this year. Despite treatment advances, more than 40,000 deaths are expected.
Resistance to therapies poses a meaningful challenge. This stems from the disease’s heterogeneity and mutations affecting genes like ESR1, NF1, and HER2, which can lead to resistance against antiestrogens, CDK4/6 inhibitors, and PI3K inhibitors.
The study, analyzing 3,880 breast cancer samples, found a link between mutations and APOBEC3 enzymes. These enzymes, while aiding the body in fighting viruses, can also trigger DNA changes that promote cancer. The APOBEC3 enzymes A3A and A3B induce mutations in resistance-associated genes like RB1,ESR1,and ARID1A. Higher APOBEC3 levels correlate with poorer outcomes and tamoxifen resistance in estrogen receptor-positive BC. These mutation patterns are more prevalent in metastatic BC and may facilitate cancer’s adaptation during hormone therapy.
researchers noted that APOBEC3 signatures were present in 60% of APOBEC3-dominant tumors at earlier stages, with 95% showing A3A or A3B protein expression, suggesting early APOBEC3 activity.
APOBEC3 activity shows promise as a predictive biomarker, potentially identifying tumors prone to evolution and therapy resistance before treatment begins. The study also points to therapeutic vulnerabilities in APOBEC3-dominant tumors, including a dependence on the PI3K pathway and a high tumor mutational burden, potentially increasing responsiveness to immune checkpoint inhibitors.
These findings suggest that APOBEC3-based biomarkers could guide the use of existing therapies and the advancement of targeted treatment strategies. However, limitations such as reliance on targeted panel sequencing and the focus on ER-positive tumors call for larger, diverse studies to fully understand the role of APOBEC3 mutagenesis across all BC subtypes and stages.
The researchers stated that the pre-existence of APOBEC3 in breast cancer allows for the development of biomarkers capable of detecting underlying evolvability before therapy. They believe such biomarkers are a crucial step toward treatment strategies that overcome resistance and limit unneeded therapies to those not at risk of such evolution.
What’s next
Future research will focus on validating these findings in larger, more diverse patient groups and exploring the clinical utility of APOBEC3-based biomarkers in guiding treatment decisions for breast cancer patients.